Update of safety profile of levonorgestrel: a disproportionality analysis based on FAERS from 2004 to 2023

被引：0
作者：
Lai, Wujiang [1 ]
Liang, Jiemei [1 ]
Xiang, Ying [2 ]
Hu, Qinqin [1 ]
Huang, Jinfa [1 ]
Chen, Milin [1 ]
Chen, Xiting [1 ]
Sun, Bin [1 ]
Yang, Qian [1 ]
Deng, Kaixian [1 ]
机构：
[1] Southern Med Univ, Shunde Hosp, Peoples Hosp Shunde 1, 1 Jiazi Rd, Foshan 528300, Peoples R China
[2] Sixth Med Ctr PLA Gen Hosp, Sr Dept Tradit Chinese Med, Beijing, Peoples R China
来源：
EXPERT OPINION ON DRUG SAFETY | 2025年
关键词：
Levonorgestrel; progesterone; real world analysis; adverse events reports; FAERS database; IDIOPATHIC INTRACRANIAL HYPERTENSION; EMERGENCY CONTRACEPTION; INTRAUTERINE SYSTEMS; MEFENAMIC-ACID; PREGNANCY; WOMEN; IMPLANT; DEVICE; RISK; MIFEPRISTONE;
D O I：
10.1080/14740338.2025.2472908
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
BackgroundLevonorgestrel has been utilized in emergency contraception (EC) and for endometrial conditions. While abnormal uterine bleeding is a recognized adverse event (AE), other potential AEs remain undocumented.Research design and methodsSafety data for levonorgestrel were acquired from the United States FDA Adverse Event Reporting System (FAERS) database, covering the period from the first quarter (Q1) of 2004 to the fourth quarter (Q4) of 2023. A disproportionality analysis was conducted to assess the association between levonorgestrel and AEs.ResultsA total of 136,168 AEs associated with levonorgestrel were reported. 106 preferred terms (PTs) and 2 system organ class (SOCs) met the criteria established by four algorithms. The identified PTs were vaginal hemorrhage, irregular menstruation, genital hemorrhage and so on. The SOCs encompassed reproductive system and breast disorders, as well as pregnancy, puerperium, and perinatal conditions.ConclusionsAlthough most findings align with the existing drug inserts for levonorgestrel, several novel AEs were identified in our study. Therefore, ongoing monitoring of this drug is essential and its safety profile should be updated regularly to enhance clinical practice regulation.
引用
收藏
页数：9
相关论文
共 84 条
  • [1] Bearak J., Popinchalk A., Ganatra B., Et al., Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019, Lancet Glob Health, 8, 9, pp. e1152-e1161, (2020)
  • [2] Consensus statement on emergency contraception, Contraception, 52, 4, pp. 211-213, (1995)
  • [3] Mazer-Amirshahi M., Ye P., Emergency contraception in the emergency department, Am J Emerg Med, 63, pp. 102-105, (2023)
  • [4] Yuzpe A.A., Lancee W.J., Ethinylestradiol and dl-norgestrel as a postcoital contraceptive, Fertil Steril, 28, 9, pp. 932-936, (1977)
  • [5] Turok D.K., Gero A., Simmons R.G., Et al., Levonorgestrel vs. Copper intrauterine devices for emergency contraception, N Engl J Med, 384, 4, pp. 335-344, (2021)
  • [6] Glasier A.F., Cameron S.T., Fine P.M., Et al., Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis, Lancet, 375, 9714, pp. 555-562, (2010)
  • [7] Lee S.M., Dunn S., Evans M.F., Levonorgestrel versus the “Yuzpe” regimen. New choices in emergency contraception, Can Fam Physician, 45, pp. 629-631, (1999)
  • [8] Durand M., Del Carmen Cravioto M., Raymond E.G., Et al., On the mechanisms of action of short-term levonorgestrel administration in emergency contraception, Contraception, 64, 4, pp. 227-234, (2001)
  • [9] Hapangama D., Glasier A.F., Baird D.T., The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle, Contraception, 63, 3, pp. 123-129, (2001)
  • [10] Trussell J., Ellertson C., Stewart F., Et al., The role of emergency contraception, Am J Obstet Gynecol, 190, 4, pp. S30-S38, (2004)
123456789